No Data
No Data
Achieve, INmune, Lenz Gain on Bullish Initiations From Raymond James
Raymond James Initiates LENZ Therapeutics(LENZ.US) With Buy Rating, Announces Target Price $37
LENZ Therapeutics to Participate in Upcoming Investor Conferences
LENZ Therapeutics, Inc. (LENZ) Q2 2024 Earnings Call Transcript
LENZ Therapeutics Price Target Maintained With a $36.00/Share by Piper Sandler
LENZ Therapeutics Is Maintained at Overweight by Piper Sandler
No Data
No Data